KSC · 001060.KS
JW Pharmaceutical Corporation
₩23,000-₩150 (-0.65%)
JW Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 41.4% below the high.
Loading market information…
KSC · 170900.KS · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Dong-A ST Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.82% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Dong-A ST Co., Ltd.’s forward annual dividend is ₩700 per share, paid annual. The forward yield is 2.07% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Dong-A ST Co., Ltd.’s next earnings report is currently expected on Mar 24, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dong-A ST Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₩182.09B+17.7% vs estimate |
| Q4 2024 | Feb 10, 2025 | ₩1,761 | ₩178.62B+4.34% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩23,000-₩150 (-0.65%)
JW Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 41.4% below the high.
₩3,670-₩30 (-0.81%)
Bukwang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 62.89% below the high.
₩9,500-₩10 (-0.11%)
HLB Pharmaceutical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 57.3% below the high.
₩7,730-₩70 (-0.9%)
EuBiologics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 56.33% below the high.
₩6,930-₩550 (-7.35%)
FutureChem Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 75.22% below the high.
₩16,960-₩70 (-0.41%)
Huons Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 59.13% below the high.
₩931₩0 (0.0%)
Yungjin Pharm. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 59.87% below the high.
₩2,350-₩80 (-3.29%)
BNC Korea Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.97% below the high.
